Guidelines for using verteporfin (Visudyne®) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes

Retina

Volumn 22, Issue 1, 2002, Pages 6-18

[No Author Info available]

Author keywords

Age related macular degeneration; Choroidal neovascularization guidelines photodynamic therapy; Randomized clinical trials; Verteporfin therapy

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT; PORPHYRIN;

AGE DISTRIBUTION; ARTICLE; BIOMICROSCOPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SCREENING; EXTRAVASATION; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; LASER COAGULATION; MYOPIA; PATIENT SELECTION; PHOTODYNAMIC THERAPY; PRACTICE GUIDELINE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; SUNLIGHT; TREATMENT OUTCOME; VISUAL ACUITY; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; PHOTOCHEMOTHERAPY; RETINA MACULA DEGENERATION; TIME;

CHOROIDAL NEOVASCULARIZATION; FLUORESCEIN ANGIOGRAPHY; HUMANS; MACULAR DEGENERATION; PATIENT SELECTION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RANDOMIZED CONTROLLED TRIALS; TIME FACTORS; VISUAL ACUITY;

EID: 0036480513     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006982-200202000-00003     Document Type: Article

References (10)

1. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. One-year results of 2 randomized clinical trials - TAP Report 1. Arch Ophthalmol 1999;117:1329-1345.
2. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials - TAP Report 2. Arch Ophthalmol 2001;119:198-207.
3. Verteporfin In Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - Verteporfin In Photodynamic Therapy Report 2. Am J Ophthalmol 2001;131:541-560.
4. Verteporfin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial - VIP Report No. 1. Ophthalmology 2001;108:841-852.
5. Packo KH, Dwarakanathan S, Orth DH, Flood TP. Comparison of standardized MPS protocol visual acuity and non-standardized Snellen acuity in age-related macular degeneration [abstract]. Invest Ophthalmol Vis Sci 2001;42:S449.
6. Tunis SR, Patel SB, Rotter PS, Londner M. Medicare coverage policy - decisions. Ocular photodynamic therapy with verteporfin (#CAG-00066). Decision memorandum. Available at: http://www.hcfa.gov/coverage/8b3-ee5.htm. Accessed November 8, 2000.
7. Reinke MH, Canakis C, Husain D, et al. Verteporfin photodynamic therapy retreatment of normal retina and choroid in the cynomolgus monkey. Ophthalmology 1999;106:1915-1923.
8. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Verteporfin (Visudyne) therapy of subfoveal choroidal neovascularization in age-related macular degeneration. Impact of baseline lesion composition on one- and two-year vision outcomes - TAP Report 3. Arch Ophthalmol 2002 (in press).
9. Rosenfeld PJ, Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Visual outcomes in patients with minimally classic choroidal neovascularization (CNV): rationale for the Visudyne In Minimally classic CNV (VIM) Trial [abstract]. Invest Ophthalmol Vis Sci 2001;42:S512.
10. Houle J, Bain S, Azab M, Strong A. Clinical pharmacokinetics of verteporfin in healthy volunteers and patients with CNV [abstract]. Invest Ophthalmol Vis Sci 2001;42:S437.